WO2008085898A3 - Methods for identifying essential proteins and therapeutic agents - Google Patents

Methods for identifying essential proteins and therapeutic agents Download PDF

Info

Publication number
WO2008085898A3
WO2008085898A3 PCT/US2008/000131 US2008000131W WO2008085898A3 WO 2008085898 A3 WO2008085898 A3 WO 2008085898A3 US 2008000131 W US2008000131 W US 2008000131W WO 2008085898 A3 WO2008085898 A3 WO 2008085898A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
therapeutic agents
essential proteins
identifying essential
identifying
Prior art date
Application number
PCT/US2008/000131
Other languages
French (fr)
Other versions
WO2008085898A2 (en
Inventor
Joan Brugge
Hanna Y Irie
Original Assignee
Harvard College
Joan Brugge
Hanna Y Irie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Joan Brugge, Hanna Y Irie filed Critical Harvard College
Publication of WO2008085898A2 publication Critical patent/WO2008085898A2/en
Publication of WO2008085898A3 publication Critical patent/WO2008085898A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

The invention features methods of identifying compounds that selectively interfere with anchorage independent cell survival and methods of diagnosing a subject as having, or having the propensity to develop, a proliferative disorder (e.g., cancer).
PCT/US2008/000131 2007-01-04 2008-01-04 Methods for identifying essential proteins and therapeutic agents WO2008085898A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87855507P 2007-01-04 2007-01-04
US60/878,555 2007-01-04

Publications (2)

Publication Number Publication Date
WO2008085898A2 WO2008085898A2 (en) 2008-07-17
WO2008085898A3 true WO2008085898A3 (en) 2008-10-16

Family

ID=39609265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/000131 WO2008085898A2 (en) 2007-01-04 2008-01-04 Methods for identifying essential proteins and therapeutic agents

Country Status (1)

Country Link
WO (1) WO2008085898A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017371559A1 (en) * 2016-12-08 2019-07-04 National University Of Singapore Anti-cancer compounds and uses thereof
CN115044667A (en) * 2018-09-21 2022-09-13 王赞鑫 SNP (single nucleotide polymorphism) site related to aortic dissection disease and application thereof
EP4051796A1 (en) * 2019-11-01 2022-09-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150091A (en) * 1996-03-06 2000-11-21 Baylor College Of Medicine Direct molecular diagnosis of Friedreich ataxia
US6727063B1 (en) * 1999-09-10 2004-04-27 Millennium Pharmaceuticals, Inc. Single nucleotide polymorphisms in genes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150091A (en) * 1996-03-06 2000-11-21 Baylor College Of Medicine Direct molecular diagnosis of Friedreich ataxia
US6727063B1 (en) * 1999-09-10 2004-04-27 Millennium Pharmaceuticals, Inc. Single nucleotide polymorphisms in genes

Also Published As

Publication number Publication date
WO2008085898A2 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
WO2008033408A3 (en) Methods for identifying compounds that modulate cell signaling and methods employing such compounds
WO2009077857A3 (en) Trail variants for treating cancer
CU20120095A7 (en) PCSK9 ANTAGONISTS
MX2009008470A (en) Particles for detecting intracellular targets.
WO2010009337A3 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
MX2009008430A (en) Anti-robo4 antibodies and uses therefor.
WO2008079326A3 (en) Methods for using and identifying modulators of delta-like 4
MX2009008347A (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use.
WO2010017515A3 (en) Breast cancer specific markers and methods of use
TN2010000213A1 (en) Wise binding antibodies and epitopes
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
WO2006125962A3 (en) T cell receptors which specifically bind to vygfvracl-hla-a24
MX2009012625A (en) Methods of treating, diagnosing and detecting fgf21-associated disorders.
EP1950554A4 (en) Mixture identifying system
WO2010003520A3 (en) Anti-tumor immunotherapy
DOP2011000183A (en) POLYMORPHES OF (S) -3-AMINO-METHYL-7- (3-HIDROXI-PROPOXI) -3H-BENZO- [C] [1,2-OXABOROL-1-OL
ZA200707962B (en) Novel resorcinol derivatives
WO2007149476A3 (en) Assays for non-apoptotic cell death and uses thereof
EP2281903A4 (en) Cancer marker, method for evaluation of cancer by using the cancer marker, and evaluation reagent
WO2010104598A3 (en) Kinase protein binding inhibitors
WO2009113814A3 (en) Protein marker for early diagnosis of liver cancer
PL2140269T3 (en) Protein signature/markers for the detection of adenocarcinoma
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer
WO2009140557A3 (en) Modified release tolterodine formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08713004

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08713004

Country of ref document: EP

Kind code of ref document: A2